MHRA Publishes New Terminated, Cancelled Medicine Licences List

• The MHRA publishes regular lists of terminated, cancelled, and revoked manufacturing and wholesale dealer licences in the UK.
• Licence termination occurs at the holder's request, while cancellation is an MHRA decision.
• These lists are frequently updated, with records available from August 2023 through September 2026.
• The September 2026 list is provided as a 18.9 KB CSV file, which may not be suitable for assistive technology users.
• The information is crucial for verifying the regulatory status of UK pharmaceutical companies.

The continuous publication of the MHRA terminated cancelled medicine licences list holds significant implications for the integrity and compliance of the UK pharmaceutical supply chain.

The Medicines and Healthcare products Regulatory Agency (MHRA) routinely publishes comprehensive lists detailing the status of manufacturing and wholesale dealer licences for pharmaceutical companies operating within the United Kingdom. These crucial updates, which include licences that have been terminated, cancelled, or revoked, are vital for maintaining transparency and regulatory oversight in the UK's pharmaceutical sector. The MHRA's commitment to regularly updating this information ensures that stakeholders have access to the most current regulatory standing of various entities.

These lists specifically identify UK companies whose authorization to produce or distribute medicines has been withdrawn for various reasons. The information is made available through official government channels, with the most recent data point being a CSV file for September 2026, which is approximately 18.9 KB in size. It is noted that this particular file may present accessibility challenges for users relying on assistive technology, a detail the MHRA acknowledges.

The MHRA distinguishes between different reasons for a licence no longer being active. A "termination" of a licence, authorisation, or registration occurs when the licence holder themselves initiates the cessation. This typically happens when a business decides it no longer wishes to engage in an activity that necessitates such regulatory approval, thereby requesting the termination of their authorization. This process is driven by the company's own operational decisions.

In contrast, a "cancellation" of a licence, authorisation, or registration is a decision made directly by the Medicines and Healthcare products Regulatory Agency. This action signifies that the MHRA has determined that the licence should no longer be valid, often due to non-compliance or other regulatory infractions. While the source also mentions "revoked" licences in the list titles, it specifically defines the processes for termination and cancellation, highlighting the distinct regulatory pathways that lead to a licence being removed from active status.

The continuous publication of the MHRA terminated cancelled medicine licences list holds significant implications for the integrity and compliance of the UK pharmaceutical supply chain. These lists serve as an essential resource for monitoring the operational status of companies holding manufacturing and wholesale dealer licences. Regularly consulting these updates is critical for businesses, legal professionals, and compliance officers to ensure they are engaging with authorized entities and to mitigate regulatory risks.

The availability of these detailed records, which track changes in licence status over time, allows for thorough due diligence. For instance, the MHRA has consistently updated these lists, with records extending back to August 2023 and continuing through to September 2026. This ongoing effort to provide current and historical data underscores the importance of verifying the MHRA licence status check for any UK pharmaceutical operation, ensuring that all parties adhere to the necessary regulatory standards.

The Medicines and Healthcare products Regulatory Agency maintains a rigorous schedule for updating its records of manufacturing and wholesale dealer licence cancellations and terminations. This commitment is evident from the extensive history of updates provided on their official channels. Recent updates include specific lists published for September 2026, August 2026, July 2026, June 2026, May 2026, April 2026, March 2026, and February 2026.

Further historical data shows updates for December 2025, November 2025, September 2025, August 2025, July 2025, and June 2025. The agency also released updated lists for May 2025, December 2024, November 2024, October 2024, September 2024, August 2024, July 2024, May 2024, April 2024, and February 2024. This consistent effort to publish the MHRA terminated cancelled medicine licences list extends back to December 2023, November 2023, and August 2023, demonstrating a sustained focus on transparently reporting UK pharmaceutical licence revocation statuses.

Lawyers and compliance officers should regularly consult the MHRA's updated lists of terminated, cancelled, and revoked manufacturing and wholesale dealer licences. This is crucial for ensuring client compliance, conducting due diligence on business partners, and assessing regulatory risks within the UK pharmaceutical supply chain, as it identifies entities no longer authorized to operate.

Source: Original reporting via GOV.UK